Komentarz do badań STAMPEDE, CHAARTED i LATITUDE z punktu widzenia urologa i onkologa klinicznego Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2018
Słowa kluczowe:
rak gruczołu krokowego, terapia hormonalna, docetaksel, abirateron
##plugins.themes.bootstrap3.article.main##
Abstrakt
Stosowanie leczenia hormonalnego powodującego obniżenie stężenia testosteronu w surowicy stanowi zasadniczy sposób leczenia chorych na zaawansowanego raka gruczołu krokowego. Badania STAMPEDE, CHAARTED i LATITUDE pokazały, że wczesne dołączenie docetakselu lub abirateronu do leczenia hormonalnego istotnie wydłuża przeżycie chorych w porównaniu z tymi, u których to leczenie wprowadzano w chwili progresji choroby nowotworowej.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Dobruch, J., & Drobniak , A. (2018). Komentarz do badań STAMPEDE, CHAARTED i LATITUDE z punktu widzenia urologa i onkologa klinicznego . Medycyna Faktów , 11(3(40), 216-223. https://doi.org/10.24292/01.MF.0318.8
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Torre L.A., Bray F., Siegel R.L. et al.: Global cancer statistics 2012. C.A. Cancer J. Clin. 2015; 65: 87-108.
2. Paquette E.L., Sun L., Paquette L.R. et al.: Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002; 60: 756-759.
3. Weiner A.B., Matulewicz R.S., Eggener S.E., Schaeffer E.M.: Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016; 19: 395-397.
4. Kitagawa Y., Namiki M.: Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia. Asian J. Androl. 2015; 17: 475-480.
5. Huggins C., Hodges C.V.: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293-297.
6. Walsh P.C.: Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol. Clin. N. Am. 1975; 2: 125-140.
7. Denis L.: Prostate cancer. Primary hormonal treatment. Cancer 1993; 71: 1050-1058.
8. Hellerstedt B.A., Pienta K.J.: The current state of hormonal therapy for prostate cancer. C.A. Cancer J. Clin. 2002; 52: 154-179.
9. Petrylak D.P., Tangen C.M., Hussain M.H. et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004; 351: 1513-1520.
10. Tannock I.F., de Wit R., Berry W.R. et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502-1512.
11. Sweeney C.J., Chen Y.H., Carducci M. et al.: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 2015; 373: 737-746.
12. James N.D., Sydes M.R., Clarke N.W. et al.: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163-1177.
13. Fizazi K., Tran N., Fein L. et al.: Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 2017; 377: 352-360.
14. Gravis G., Boher J.M., Chen Y.H. et al.: Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur. Urol. 2018; 73(6): 847-855. DOI: 10.1016/j.eururo.2018.02.001.
15. Mottet N., De Santis M., Briers E. et al.: Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. Eur Urol. DOI: 10.1016/j.eururo.2017.09.029.
16. Sydes M.R., Spears M.R., Mason M.D. et al.: Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann. Oncol. 2018; 29(5): 1235-1248. DOI: 10.1093/annonc/mdy072.
17. Østergren P.B., Kistorp C., Fode M. et al.: Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial. J. Urol. 2017; 197: 1441-1447.
2. Paquette E.L., Sun L., Paquette L.R. et al.: Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002; 60: 756-759.
3. Weiner A.B., Matulewicz R.S., Eggener S.E., Schaeffer E.M.: Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016; 19: 395-397.
4. Kitagawa Y., Namiki M.: Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia. Asian J. Androl. 2015; 17: 475-480.
5. Huggins C., Hodges C.V.: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293-297.
6. Walsh P.C.: Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol. Clin. N. Am. 1975; 2: 125-140.
7. Denis L.: Prostate cancer. Primary hormonal treatment. Cancer 1993; 71: 1050-1058.
8. Hellerstedt B.A., Pienta K.J.: The current state of hormonal therapy for prostate cancer. C.A. Cancer J. Clin. 2002; 52: 154-179.
9. Petrylak D.P., Tangen C.M., Hussain M.H. et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004; 351: 1513-1520.
10. Tannock I.F., de Wit R., Berry W.R. et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502-1512.
11. Sweeney C.J., Chen Y.H., Carducci M. et al.: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 2015; 373: 737-746.
12. James N.D., Sydes M.R., Clarke N.W. et al.: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163-1177.
13. Fizazi K., Tran N., Fein L. et al.: Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 2017; 377: 352-360.
14. Gravis G., Boher J.M., Chen Y.H. et al.: Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur. Urol. 2018; 73(6): 847-855. DOI: 10.1016/j.eururo.2018.02.001.
15. Mottet N., De Santis M., Briers E. et al.: Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. Eur Urol. DOI: 10.1016/j.eururo.2017.09.029.
16. Sydes M.R., Spears M.R., Mason M.D. et al.: Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann. Oncol. 2018; 29(5): 1235-1248. DOI: 10.1093/annonc/mdy072.
17. Østergren P.B., Kistorp C., Fode M. et al.: Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial. J. Urol. 2017; 197: 1441-1447.